Bharat Parenterals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 15 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.0K Cr
Standalone business: - Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores base. Innoxel Lifesciences: Expected revenue growth of 35%-45% in FY '27 with EBITDA margins of 20%-25%.
From Bharat Parenterals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,397
Market Cap
₹1.0K Cr
Revenue Rank
Margin Rank
How does Bharat Parenterals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Bharat Parenterals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Bharat Parenterals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹100 Cr, net profit ₹-8 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →Standalone business:
- → - Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores base.
- → - Full recovery and crossing FY '25 numbers anticipated by FY '28.
- → - Long-term peak revenue target of INR 400-500 crores by 2030.
- → - Growth driven by Southeast Asia, Africa, and MENA regions.
- →Innoxel Lifesciences:
- → - Revenue growth of 35% to 45% expected in FY '27.
- → - Commercial CMO supply starting Q2 FY '27 with 2-3 products commercializing.
- → - 10 new filings and 20 partner deals planned in FY '27.
- → - Strong manufacturing revenues and out-licensing milestones expected to start FY '28.
- →Varenyam Healthcare:
- → - Revenue growth of 20% to 25% forecast in FY '27.
- → - Expansion of field force to over 250 people.
- → - Introduction of 7 new products including India's first made-in-India Sugammadex.
- →Varenyam Biolifesciences:
- → - Pre-revenue through FY '27.
- → - Facility commissioning by Sept 2027 and manufacturing validation by March 2028.
- → - First commercial supplies expected Q4 FY '29.
📈 Profitability & Margins
Rank 1- →Innoxel Lifesciences: Expected revenue growth of 35%-45% in FY '27 with EBITDA margins of 20%-25%. Commercial supply of 2-3 CMO products starting Q2 FY '27; 10 new filings planned; out-licensing income targeted between INR 70-90 crores.
- →Standalone Business (BPL): Anticipated 10%-15% revenue growth for FY '27 with EBITDA margins in the same range. Full recovery to FY '25 revenue levels expected by FY '28, reaching INR 400-500 crores top line by FY '30.
- →Varenyam Healthcare: Revenue growth projected at 20%-25% with EBITDA margins of 8%-13% in FY '27. Expansion of field force and new product launches planned.
- →Varenyam Biolifesciences (Complex Injectables): Pre-revenue in FY '27; commercial supply expected from Q4 FY '29 following regulatory filings starting Q1 FY '29.
- →Overall, focus on regulatory approvals, milestone payments, and capacity utilization to drive margin expansion and profit growth over the next 3-4 years.
🏗️ Capital Expenditure Plans
Yes- →Varenyam Biolifesciences (VBPL) is undergoing capital investment with an approved budget of around INR 160 crores for building a complex injectable manufacturing facility.
- →As of FY '26 year-end, around INR 33 crores has been spent (20% of the budget).
- →Key milestones include commissioning manufacturing lines by September 2027 and validation by March 2028.
- →The facility aims for first regulatory filing under EUGMP in Q1 FY '29 and commercial supply by Q4 FY '29.
- →Standalone business completed facility upgrades last year including general injectable vial line, water system in beta-lactam block, preparing for upcoming PIC/S and EUGMP inspections in FY '27. These were one-time capex activities causing some production downtime.
- →No fresh capital expenditure is currently needed to grow the standalone business by 10-15% in FY '27 due to existing capacity headroom.
💰 Fundraising & Capital Structure
No information- →The company has been transparent about the cash requirements for Varenyam Biolifesciences, indicating funding needs during its construction and validation phases.
- →No explicit mention of any immediate or planned new fundraising through debt or equity in the current or near future was provided.
- →The management emphasized giving confident ranges rather than precise estimates for cash requirements.
- →Investments are ongoing, particularly in subsidiaries and field force expansions, implying internal cash flow management and careful financial planning.
- →No announcements or guidance on fresh equity issuance or new debt raising were disclosed in the Q4 FY '26 call or transcript.
📋 Order Book & Pipeline
No information- →The standalone business has an order book of INR 171 crores, providing reasonable visibility for FY '27.
- →The $27 million ($27 million approx.) tender order for high-demand pharmaceutical products in the standalone business was delayed but has started supply in 2026, with 90% expected to be covered within the year.
- →Innoxel has 20 targeted new partner deals in the pipeline, with 10 in advanced stages of discussions and due diligence.
- →Innoxel expects to file 10 new products in FY '27.
- →Varenyam Biolifesciences is pre-revenue through FY '27, focusing on commissioning and regulatory milestones, with first commercial supply expected in Q4 FY '29.
- →The standalone business growth is expected at 10%-15% in FY '27, supported by existing order book and market expansions.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Bharat Parenterals Ltd Q4 FY26 results?
Standalone business: - Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores base. Innoxel Lifesciences: Expected revenue growth of 35%-45% in FY '27 with EBITDA margins of 20%-25%.
What is Bharat Parenterals Ltd share price analysis?
Bharat Parenterals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹1,007 Cr. Investors should review the full earnings analysis for detailed insights.
Is Bharat Parenterals Ltd planning capital expenditure?
Varenyam Biolifesciences (VBPL) is undergoing capital investment with an approved budget of around INR 160 crores for building a complex injectable manufacturing facility. - As of FY '26 year-end, around INR 33 crores has been spent (20% of the budget). - Key milestones include commissioning manufacturing lines by September 2027 and validation by March 2028. - The facility aims for first regulatory filing under EUGMP in Q1 FY '29 and commercial supply by Q4 FY '29. - Standalone business completed facility upgrades last year including general injectable vial line, water system in beta-lactam block, preparing for upcoming PIC/S and EUGMP inspections in FY '27.
Keep Bharat Parenterals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.